Frontotemporal dementia (FTD), in particular, may be at play, and identifying ways to slow down its progression can help. In ...

Donanemab and lecanemab have been shown to delay progression from mild to moderate Alzheimer's by up to six months but are ...

Revolutionary artificial intelligence glasses for dementia sufferers can 'see' objects and project prompts on to lenses to ...

Oral semaglutide (a GLP-1 pill) is not effective at slowing progression in patients with mild Alzheimer's disease, finds the ...

In TODAY.com's Expert Tip of The Day, a neurologist explains how playing games that build cognitive speed can protect against ...

Professor Fiona Carragher, chief policy and research officer at Alzheimer’s Society, said: “Rapid advancements in AI will give people affected by early-stage dementia the opportunity to stay safely in ...

A major new study finds people with type 1 diabetes face nearly three times the dementia risk. But lifestyle changes and new treatments offer real hope.

New analyses show DLB patients with lower plasma pTau181 levels - indicating an earlier stage of disease and absence of ...

New research demonstrates that preclinical cognitive decline may be identifiable through subtle language shifts. An analysis ...

New AI glasses for people with dementia ‘see’ objects and project visual prompts onto the lenses to help them live ...

The results of the EVOKE and EVOKE+ trials were comprehensive in showing oral semaglutide’s lack of clinical efficacy for cognition or function in patients with early Alzheimer’s.

Village Green Unveils Expanded Memory Care Framework Across Cypress, Dallas & Tomball — Setting New Standards for ...